Bayesian Capital Management’s Enfusion, Inc. ENFN Stock Holding History

Bayesian Capital Management’s Portfolio ENFN Stock Details ENFN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,554	Closed	-$111K	–	1110
2023 Q1	$111K	Buy	+10,554	New	+$116K	0.01%	675

Other funds holding ENFN

FMC

FTV Management Company San Francisco, California $541M AUM 34.37% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Ararat Capital Management Westport, Connecticut $178M AUM 26.61% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return

Bayesian Capital Management's ENFN Position: Q2 2023 in Review

Bayesian Capital Management sold out of Enfusion, Inc. (ENFN) in Q2 2023, closing a stake of 10,554 shares — an estimated $111K sold.

Bayesian Capital Management first reported a position in ENFN in Q1 2023 and held it in 1 quarter. The position peaked at $111K in Q1 2023. 83 funds tracked by Wall St. Rank hold ENFN as of Q2 2023.

Bayesian Capital Management reported no remaining Enfusion, Inc. position as of Q2 2023 after selling out during the quarter.
Bayesian Capital Management sold 10,554 Enfusion, Inc. shares in Q2 2023, an estimated $111K.
Bayesian Capital Management first reported a position in Enfusion, Inc. in Q1 2023 and held it in 1 quarter.
Bayesian Capital Management's Enfusion, Inc. position peaked at $111K in Q1 2023.
83 funds tracked by Wall St. Rank held Enfusion, Inc. as of Q2 2023.

Based on Bayesian Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.